CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
lubiprostone +2 moredrug
Likely dose
lubiprostone 24 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00953043
NCT00953043Phase 4Completed
CompareCT.gov

The Effect of Lubiprostone, a Chloride Channel Activator, on Colonic Sensorimotor Functions in Healthy Subjects. A Phase IV, Placebo-Controlled, Parallel Group Study

Mayo Clinic·interventional·Posted Aug 6, 2009·Updated Feb 27, 2012

In Brief

A Phase 4 clinical trial evaluating lubiprostone, Placebo, and 1 other intervention for Healthy. Completed, enrolled 60 participants across 1 site.

Detailed Summary

This study is being done to evaluate the effects of lubiprostone, a drug approved and used for constipation, on pattern of contractions of the colon and the colon's sensitivity to distension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Research Resources (NCRR), Takeda

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 6, 2009
Enrollment StartSep 1, 2007
Primary CompletionJul 1, 2008
Study CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.9 years ago

Interventions

lubiprostonedrug

Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects

Placebodrug

Placebo medication given for three days

Bowel preparationother

Polyethylene glycol-based bowel preparation